$OVID News
Last published 1d ago
- 1d agoOVIDOvid Therapeutics Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 6d agoOVIDOvid Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireNEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today
- 3w agoATNMCRMDOVIDActinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial OfficerPR NewswireNEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment
- 2mo agoOVIDOvid Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireNEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today
- 3mo agoOVIDOvid Therapeutics Reports Business Updates and Second Quarter 2026 Financial ResultsGlobeNewswireFirst-ever oral direct KCC2 activator, OV4071, advancing in an ongoing Phase 1 studyInitiated Phase 2 proof-of-concept and photosensitivity studies for OV329, a next-generation GABA-AT inhibitorA newly-formed portfolio
- 4mo agoOVIDOvid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of DevelopmentGlobeNewswireKevin Norrett, a proven leader in advancing corporate strategy through value-creating transactions, will be appointed as Chief Business OfficerCharles Carter promoted to Chief Financial Officer, reflecting his strong
- 5mo agoOVIDOvid Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireNEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today
- 5mo agoOVIDOvid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of DirectorsGlobeNewswireNEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today
- 6mo agoOVIDOvid Therapeutics Reports Business Updates and First Quarter 2026 Financial ResultsGlobeNewswireDosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) direct activator, in May 2026 in a Phase 1 study with healthy volunteersOV329 showed favorable safety, tolerability,
- 7mo agoOVIDOvid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14GlobeNewswireNEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the
- 7mo agoOVIDOVID THERAPEUTICS BUSINESS AND PIPELINE UPDATE - OVID THERAPEUTICS INCEarnings Call Transcriptsyou you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you
- 7mo agoOVIDOvid Therapeutics Business and Pipeline UpdateOVID THERAPEUTICS INCEarnings Call Transcriptsyou you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you you
- 8mo agoOVIDOvid Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireNEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company developing small molecule medicines to treat brain disorders and symptoms caused by excess neural
- 10mo agoOVIDOvid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)GlobeNewswireOV350 showed a good safety profile, supporting the advancement of the Company's KCC2 portfolio, including the first oral direct activator, OV4071There were no treatment-related laboratory findings, no safety findings,
- 11mo agoOVIDOvid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical OfficerGlobeNewswireNEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the
- 12mo agoOVIDOvid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial ResultsGlobeNewswireMeg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of DirectorsNext-generation GABA-aminotransferase (GABA-AT) inhibitor, OV329,
- 1y agoOVIDOvid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross ProceedsGlobeNewswireNEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today
- 1y agoOVIDOvid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profileGlobeNewswireAn expansive biomarker study confirmed OV329 delivered statistically significant inhibition of GABA-AT as measured across multiple metricsOV329 matched or exceeded inhibition demonstrated by therapeutic doses of
- 1y agoOVIDOvid Therapeutics Reports Business Updates and Second Quarter 2025 Financial ResultsGlobeNewswireTopline results from the OV329 Phase 1 safety, tolerability and biomarker study remain on track for a readout in Q3 2025$7.0 million royalty monetization agreement signed with Immedica Pharma AB for future ganaxolone
- 1y agoOVIDOvid Therapeutics to Participate in the BTIG Virtual Biotech ConferenceGlobeNewswireNEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, announced
- 1y agoOVIDOvid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone RoyaltiesGlobeNewswireNEW YORK and STOCKHOLM, Sweden, June 25, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant
- 1y agoOVIDOvid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025GlobeNewswireNEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, will host an investor
- 1y agoOVIDOvid Therapeutics Reports Business Updates and First Quarter 2025 Financial ResultsGlobeNewswireTopline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025Ovid's first program in its KCC2 direct activator library, OV350, has been dosed in a
- 1y agoOVIDOvid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare ConferenceGlobeNewswireNEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that
- 1y agoOVIDOvid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireStelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and move its first KCC2 direct
- 1y agoOVIDOvid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of DirectorsGlobeNewswireNEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today
- 1y agoOVIDOvid Therapeutics to Present at the TD Cowen 45th Annual Health Care ConferenceGlobeNewswireNEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg
- 1y agoOVIDOvid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceGlobeNewswireNEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that
- 1y agoOVIDOvid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual MeetingGlobeNewswireTwo preclinical studies to be presented on OV329, a potential next-generation GABA aminotransferase inhibitor, highlighting its safety profile and lack of ocular accumulation relative to vigabatrin Findings to be
- 1y agoOVIDOvid Therapeutics Reports Business Updates and Third Quarter 2024 Financial ResultsGlobeNewswireA Phase 1 SAD/MAD study of OV329 is progressing as planned, and based on encouraging human safety data to date, Ovid will engage regulators about adding cohorts to increase potential dosing opportunities for Phase 2
- 2y agoOVIDOvid Therapeutics to Host Investor EventGlobeNewswireNEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced
- 2y agoOVIDOvid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with VigabatrinGlobeNewswireStudy found OV329 cleared and remained undetectable in the retina, eye, and brain tissues of mice, unlike vigabatrin which has repeatedly shown to preferentially accumulate in mouse retinas, eyes, and other tissues
- 2y agoOVIDMeg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future GrowthGlobeNewswireNEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today
- 2y agoOVIDOvid Therapeutics to Present at Upcoming September Investor ConferencesGlobeNewswireNEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today
- 2y agoOVIDOvid Therapeutics Reports Business Updates and Second Quarter 2024 Financial ResultsGlobeNewswireAppointed Dr. Amanda Banks, a tenured physician and biotech leader, as Chief Development Officer to lead clinical strategy and executionExpanded Scientific Advisory Board under the leadership of Dr. Robert Langer, adding
- 2y agoOVIDOvid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development OfficerGlobeNewswireNEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced
- 2y agoAGENAMGNCASILGND+8Ligand Reports Second Quarter 2024 Financial ResultsBusiness WireConference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast
- 2y agoOVIDOvid Therapeutics to Present at Upcoming August Investor ConferencesGlobeNewswireNEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by certain epilepsies and brain conditions,
- 2y agoOVIDOvid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and EpileptologistsGlobeNewswireNeurologists/epileptologists Dr. Imad Najm of the Cleveland Clinic Neurological Institute and the Cleveland Clinic Epilepsy Center, and Dr. Raman Sankar, the Emeritus Chief of Pediatric Neurology at UCLA Health,
- 2y agoOVIDeNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant SeizuresGlobeNewswireSustained exposure to OV329 in preclinical models reduced GABA-aminotransferase (GABA-AT) activity, increased steady state GABA levels in the brain, and induced phasic and tonic inhibitionOV329 demonstrated
- 2y agoOVIDOvid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous MalformationsGlobeNewswireThe Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse eventsSecondary endpoint results indicate that the target pharmacokinetic
- 2y agoOVIDOvid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for SoticlestatGlobeNewswireTakeda's Skyline study in Dravet syndrome narrowly missed its primary endpoint of reduction in convulsive seizure frequency and showed clinically meaningful and significant effects in multiple key secondary efficacy
- 2y agoOVIDOvid Therapeutics Reports Business Updates and First Quarter 2024 Financial ResultsGlobeNewswireTakeda has completed two Phase 3 trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome; topline data are anticipated in Takeda's H1 2024 fiscal yearA Phase 1, double-blind,
- 2y agoOVIDOvid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceGlobeNewswireNEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by
- 2y agoOVIDOvid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswireNEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions,
- 2y agoOVIDOvid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswireTwo pivotal Phase 3 clinical trials studying soticlestat as a treatment for Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) completed enrollment; Takeda anticipates topline data readout by or before September
- 2y agoOVIDOvid Therapeutics to Present at the TD Cowen 44th Annual Health Care ConferenceGlobeNewswireNEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by
- 2y agoOVIDOvid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewswireNEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by
- 2y agoOVIDOvid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)GlobeNewswirePosters with new preclinical data on the pharmacokinetic and pharmacodynamic behavior of OV329 support its profile as a potential best-in-class GABA aminotransferase inhibitor Disease models provide further evidence
- 3y agoOVIDOvid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate UpdatesGlobeNewswireReceived a $30 million payment from Ligand for the sale of a 13% interest in the potential future royalties and milestone payments owed to Ovid for soticlestat The Company extended its expected cash runway into 2026